Drugs / FKC289
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06285279 | Mar 2024 → Dec 2026 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis, immunoglobulin G4-related sclerosing disease, lupus nephritis, membranous glomerulonephritis | Nanjing University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FKC289 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06285279 ↗ |
| Modality | Cell therapy | “The autologous dual target BCMA/CD19-CAR-T cell of this study is obtained by infecting T cells with anti-BCMA/CD19-CAR lentiviral vectors.” NCT06285279 ↗ |
| Route | Intravenous | “Administration method: intravenous infusion” NCT06285279 ↗ |